These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37581108)

  • 1. Focused Jurisdictional Scan of Glomerulonephritis Medication Access in Canada: A Program Report.
    Naipaul R; Marques C; Ng J; Barbour S; Lo C; Hildebrand AM; Siu V; Prasad B; Laurin LP; Wazny LD; Armstrong S; Tran J; Sheffield M; Jauhal A; Hladunewich MA
    Can J Kidney Health Dis; 2023; 10():20543581231190227. PubMed ID: 37581108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BC Glomerulonephritis Network: Improving Access and Reducing the Cost of Immunosuppressive Treatments for Glomerular Diseases.
    Barbour S; Lo C; Espino-Hernandez G; Gill J; Levin A
    Can J Kidney Health Dis; 2018; 5():2054358118759551. PubMed ID: 29581884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
    Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C
    Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces.
    Woon DTS; Chandrasekar T; Aaron L; Basappa NS; Chi KN; Conter HJ; Gotto G; Hotte SJ; Malone S; Saad F; Shayegan B; Park-Wyllie L; Hamilton RJ
    Can Urol Assoc J; 2018 Oct; 12(10):328-336. PubMed ID: 29688882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Provincial Needs Assessment to Determine the Current State of Glomerulonephritis Care in Ontario.
    Pang J; D'Antonio C; Heale E; Boll P; Blake P; Evans JM; Hladunewich M
    Can J Kidney Health Dis; 2019; 6():2054358119877405. PubMed ID: 31565235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Provincial disparities of growth hormone coverage for young adult survivors of paediatric brain tumours across Canada.
    Hasan H; Howard F; Morgan SG; Metzger DL; Lo AC; Goddard K; Gill S; Johnson M
    Healthc Policy; 2014 Feb; 9(3):80-96. PubMed ID: 24726076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacists' Scope of Practice: Supports for Canadians with Diabetes.
    Mansell K; Edmunds K; Guirguis L
    Can J Diabetes; 2017 Dec; 41(6):558-562. PubMed ID: 29037573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of the British Columbia Glomerulonephritis network and registry: integrating knowledge generation and translation within a single framework.
    Barbour S; Beaulieu M; Gill J; Djurdjev O; Reich H; Levin A
    BMC Nephrol; 2013 Oct; 14():236. PubMed ID: 24168011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage.
    Cadarette SM; Carney G; Baek D; Gunraj N; Paterson JM; Dormuth CR
    Osteoporos Int; 2012 Apr; 23(4):1475-80. PubMed ID: 21901476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.
    Jackson EB; Hotte SJ
    Can Urol Assoc J; 2022 Nov; 16(11):E516-E522. PubMed ID: 35704937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice.
    Barbour S; Lo C; Espino-Hernandez G; Sajjadi S; Feehally J; Klarenbach S; Gill J
    Nephrol Dial Transplant; 2018 Apr; 33(4):626-634. PubMed ID: 29106654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada.
    MacPhail C; Snow S
    Curr Oncol; 2022 Mar; 29(3):2064-2072. PubMed ID: 35323366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to linked administrative healthcare utilization data for pharmacoepidemiology and pharmacoeconomics research in Canada: anti-viral drugs as an example.
    Rawson NS
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1072-9. PubMed ID: 19650154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A scorecard for osteoporosis in Canada and seven Canadian provinces.
    Kendler DL; Adachi JD; Brown JP; Juby AG; Kovacs CS; Duperrouzel C; McTavish RK; Cameron C; Slatkovska L; Burke N
    Osteoporos Int; 2021 Jan; 32(1):123-132. PubMed ID: 32712739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada.
    Knowles SR; Lee K; Paterson JM; Shah BR; Mamdani MM; Juurlink DN; Gomes T
    Can J Diabetes; 2017 Apr; 41(2):138-142. PubMed ID: 27989494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of anti-infective drug use in elderly persons in Manitoba, Nova Scotia, and Saskatchewan, Canada: relationship to drug insurance reimbursement policies.
    Sketris IS; Metge C; Shevchuk Y; Comeau DG; Kephart GC; Blackburn J; MacCara M; Laturnas A
    Am J Geriatr Pharmacother; 2004 Mar; 2(1):24-35. PubMed ID: 15555476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada.
    Gotfrit J; Shin JJW; Mallick R; Stewart DJ; Wheatley-Price P
    Oncologist; 2020 Jan; 25(1):e130-e137. PubMed ID: 31506392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive risk modelling of high resource users under different prescription drug coverage policies in Ontario and Manitoba, Canada.
    Kornas K; Sarkar J; Fransoo R; Rosella LC
    BMC Health Serv Res; 2023 Jul; 23(1):768. PubMed ID: 37468878
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.